Are Stars Finally Aligning For Takeda In India?
This article was originally published in PharmAsia News
Executive Summary
For the past four years, Takeda’s plans for a full-scale entry into India have remained just that – plans on paper. But will it be a laggard for much longer in this fast-changing key emerging market? There are signs that the time may now be ripe for Japan’s top pharma firm to take a more decisive plunge.
You may also be interested in...
From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India
MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market
Eisai Opens Fourth Knowledge Center In India As Launch Pad For Next-generation Global Products; Focus On Affordability
Sitting on a 50-acre campus at Southern India's Jawaharlal Nehru Pharma City, Eisai's newly minted Knowledge Center India is the company's first integrated facility that includes API production and research functions in one site, bringing the company one step further toward creating a global supply and research hub
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.